A Trial to Determine the Efficacy and Safety of Presendin in IIH

Stopped Following a strategic evaluation of its IIH EVOLVE Phase III clinical trial investigating Presendin™, the Invex Board has made the difficult decision that the continuation of the trial is not viable and therefore the trial has been terminated.

Conditions

• Idiopathic Intracranial Hypertension

Interventions

• DRUG: Presendin
• DRUG: Placebo

Sponsor

Invex Therapeutics Ltd.

Collaborators

• [object Object]
• [object Object]
• [object Object]